Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Rubio

Showing results (241-250 of 280) with videos related to

Pageof 28
Sort By:
Ophthalmology|February 24, 2015
Author reply: To PMID 24393349Sophie J Bakri, Darius M Moshfeghi, Steve Francom, et al.
Biochimica Et Biophysica Acta|December 27, 1995
Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lungG Giaccone, J van Ark-Otte, G Scagliotti, et al.
Neurology|January 31, 2024
Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled TrialCynthia L Comella, Joseph Jankovic, Robert A Hauser, et al.
Journal of the American Academy of Dermatology|December 4, 2019
DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)Vince Bertucci, Nowell Solish, Joely Kaufman-Janette, et al.
Journal of the American Academy of Dermatology|October 8, 2025
Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE studyKim A Papp, Shahram Jacobs, Howard Sofen, et al.
Allergologia Et Immunopathologia|June 3, 1999
[Round Table: Urticaria in relation to infections]A Bilbao, J M García, I Pocheville, et al.
Clinical and Translational Science|November 28, 2024
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK-001 using a randomized, double-blind, placebo-controlled study designSibel Ucpinar, Joyce K Kwan, Joshua D Hoffman, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|September 6, 2005
The TaqIA polymorphism linked to the DRD2 gene is related to lower attention and less inhibitory control in alcoholic patientsR Rodríguez-Jiménez, C Avila, G Ponce, et al.
Cell Death and Differentiation|September 3, 2013
Mechanisms of haptoglobin protection against hemoglobin peroxidation triggered endothelial damageC A Schaer, J W Deuel, A G Bittermann, et al.
Actas Luso-Espanolas De Neurologia, Psiquiatria Y Ciencias Afines|May 1, 1987
[Psychic symptomatology in thrombosis of the upper longitudinal sinus. Apropos of a case]J R López-Trabada Gómez, J Pascual Arriazu, G Rubio Valladolid, et al.
Pageof 28

Showing results (241-250 of 280) with videos related to

Sort By:
Pageof 28
Ophthalmology|February 24, 2015
Author reply: To PMID 24393349Sophie J Bakri, Darius M Moshfeghi, Steve Francom, et al.
Biochimica Et Biophysica Acta|December 27, 1995
Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lungG Giaccone, J van Ark-Otte, G Scagliotti, et al.
Neurology|January 31, 2024
Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled TrialCynthia L Comella, Joseph Jankovic, Robert A Hauser, et al.
Journal of the American Academy of Dermatology|December 4, 2019
DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)Vince Bertucci, Nowell Solish, Joely Kaufman-Janette, et al.
Journal of the American Academy of Dermatology|October 8, 2025
Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE studyKim A Papp, Shahram Jacobs, Howard Sofen, et al.
Allergologia Et Immunopathologia|June 3, 1999
[Round Table: Urticaria in relation to infections]A Bilbao, J M García, I Pocheville, et al.
Clinical and Translational Science|November 28, 2024
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK-001 using a randomized, double-blind, placebo-controlled study designSibel Ucpinar, Joyce K Kwan, Joshua D Hoffman, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|September 6, 2005
The TaqIA polymorphism linked to the DRD2 gene is related to lower attention and less inhibitory control in alcoholic patientsR Rodríguez-Jiménez, C Avila, G Ponce, et al.
Cell Death and Differentiation|September 3, 2013
Mechanisms of haptoglobin protection against hemoglobin peroxidation triggered endothelial damageC A Schaer, J W Deuel, A G Bittermann, et al.
Actas Luso-Espanolas De Neurologia, Psiquiatria Y Ciencias Afines|May 1, 1987
[Psychic symptomatology in thrombosis of the upper longitudinal sinus. Apropos of a case]J R López-Trabada Gómez, J Pascual Arriazu, G Rubio Valladolid, et al.
Pageof 28